Participants ≥18 years of age who are/were immunocompromised at the time of initial RSVpreF vaccination, per study protocol, and will be grouped based on prior RSV vaccination history:
Group 1 will include participants naïve to any RSV vaccine.
Group 2 will include participants who received a single prior dose of RSVpreF (Abrysvo) approximately 1 year (9 to 15 months) prior to enrollment.
Group 3 will include participants who received a single prior dose of RSVpreF (Abrysvo) approximately 2 years (21 to 27 months) prior to enrollment.
Group 4 will include participants who previously received 2 doses of RSVpreF in Study C3671023 Substudy B approximately 3 years (36 to 42 months) prior to enrollment.
Participants should have a life expectancy ≥12 months (365 days) in the opinion of the investigator at enrollment.
You may not be if
Prior history of any subtype of Guillain-Barré Syndrome (GBS) of any etiology.
History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any components of the study intervention(s).
Participants with a history of transplant rejection, or PTLD, or participants who have had treatment for these conditions, within 90 days prior to study enrollment or suspected chronic humoral or cellular rejection.
Receipt of B-cell depleting therapies within 180 days prior to initial study vaccination.
Refer to the study contact for further eligibility details.
Clareo Health | A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
